Rex Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-7,142
Closed -$534K 26
2021
Q3
$534K Hold
7,142
0.28% 15
2021
Q2
$661K Hold
7,142
0.32% 16
2021
Q1
$634K Buy
+7,142
New +$708K 0.45% 16

Other funds holding ARKG

Rex Capital Advisors's ARKG Position: Q4 2021 in Review

Rex Capital Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 7,142 shares — an estimated $534K sold.

Rex Capital Advisors first reported a position in ARKG in Q1 2021 and held it in 3 quarters. The position peaked at $661K in Q2 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Rex Capital Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Rex Capital Advisors sold 7,142 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $534K.
  • Rex Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 3 quarters.
  • Rex Capital Advisors's ARK Genomic Revolution ETF position peaked at $661K in Q2 2021.
  • 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Rex Capital Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.